MUMBAI, India, July 11 -- Intellectual Property India has published a patent application (202541060213 A) filed by Dr. Bhuvaneshwari Sharannavar; Varsha V. Kaskar; Dr. Nithyananda Sastry Darbha; Dr. Parixit Bhandurge; Prakash R. Biradar; Dr. Shailendra S. Suryawanshi; Veerkumar P. Japti; and Dr. Prashant Yuvaraj Mali, Belagavi, Karnataka, on June 24, for 'develepment of process for novel darunavir pharmaceutical co-crystals formulations thereof.'
Inventor(s) include Dr. Bhuvaneshwari Sharannavar; Varsha V. Kaskar; Dr. Nithyananda Sastry Darbha; Dr. Parixit Bhandurge; Prakash R. Biradar; Dr. Shailendra S. Suryawanshi; Veerkumar P. Japti; and Dr. Prashant Yuvaraj Mali.
The application for the patent was published on July 11, under issue no. 28/2025.
According to the abstract released by the Intellectual Property India: "The present invention reveals a development of process for novel darunavir pharmaceutical cocrystals formulations thereof. More particularly, the invention relates to. the selection of drug ( Dnn mavir) and cofor111ers (Succinic acid, Niacinamide, Fumaric acid, Tartaric acid), its innovative prefomulation studies that includes UV and FTlR spectrophotometric analysis. The invention also involves development of process for pharmaccuticul co-crystals namely darunavir-succinic acid (DRY-SA) and darunavir-niacinamide (DRV-NIC) by liquid-assisted grinding (LAG) and slow solvent evaporation (SS.l) techniques. The invention also pertains to drug content analysis, saturation solubility and in-vitro drug release studies in formulated pharmaceutical co-crystals. The invention encompasses the characterization of novel darunavir pharrnaccutical co-crystals formulations by FTIR Spectroscopy, Diffel ential Scanni11g C.:dorimctry, Powder X-ray Diffractif.'n n111inc Electron Microscopy and Stability studies in compliance with Biopharmaccutics Classification System (BCS), United States Food and Drug Administration (US FDA) and Generally Recognized as Safe (GRAS). The altered size and shape of the co-crystals indicated a modified crystal habit, which led to " signilicant improvement in the solubility and dissolution properties of darunavir compared to its original form. Based on these findings; it can be concluded that co-crystals of darunavir with succinic acid and niacinamide have the potential to serve as an alternative and effective approaCh for enhancing the physicochemical properties of darunavir."
Disclaimer: Curated by HT Syndication.
